Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in advanced or recurrent cervical cancer
NCT02009579Phase 2Completed
- Sponsor
- Belgian Gynaecological Oncology Group
- Start
- Mar 2014
- Primary completion
- Jan 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 4
01
Overview
A Phase 2 trial of nintedanib in Cervical Cancer (CC), sponsored by Belgian Gynaecological Oncology Group. Started Mar 2014; status: completed.
02
Drugs
nintedanib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT02009579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02009579.